Genetesis Announces New Appointments to Executive Leadership Team
Retrieved on:
Friday, January 20, 2023
Venture Capital, Cardiology, Radiology, Biotechnology, Health, FDA, Medical Devices, Professional Services, Ecosystem, MCG, Emergency medicine, Medical director, Ascension Michigan, Cardiac catheterization, Publication, Yale Physician Associate Program, Ascension St. Mary's Hospital, De novo, Medical Affairs Bureau, Medicare, Magnetocardiography, Diagnosis, Patient, Market access, Research, Abbott Laboratories, Dipyridamole, Physician, Pain, Management, Medical device
Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced the appointment of three new members to the executive leadership team who will oversee and execute key aspects of commercialization and clinical research for its flagship solution, CardioFlux.
Key Points:
- Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced the appointment of three new members to the executive leadership team who will oversee and execute key aspects of commercialization and clinical research for its flagship solution, CardioFlux.
- This announcement comes in anticipation of market authorization from the FDA, which Genetesis expects to see later this year.
- “As we inch ever closer to the FDA granting our De Novo request, expanding our team to cover new disciplines and encompass additional experience has become critical,” said Peeyush Shrivastava, co-founder and CEO of Genetesis.
- Joining this team as we bring the promise of MCG to patients and physicians alike feels like a natural extension of the path I’ve taken thus far.”